MannKind Corp   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Elmsford NY United States (1991)

Organization Overview

First Clinical Trial
1999
NCT00511979
First Marketed Drug
2009
timolol (blocadren)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

MANNKIND | Mannkind Corporation | Pharmaceutical Discovery Corporation (PDC)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Biliary Tract Neoplasms (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Neuroendocrine (Phase 1)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Endometrial Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 1)

Gallbladder Neoplasms (Phase 1)

Hypertension (Phase 1)

Kidney Diseases (Phase 1)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Melanoma (Phase 2)

Mesothelioma (Phase 1)

Pancreatic Neoplasms (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Respiratory Aspiration (Phase 2)

Sarcoma (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Testicular Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 53
  • # of Trial APIs: 17